Actively Recruiting
Randomized Study Comparing Initial Triple Therapy Including Parenteral Treprostinil Versus Double Oral Therapy in Adults with Pulmonary Arterial Hypertension
Led by AOP Orphan Pharmaceuticals AG · Updated on 2026-10-29
110
Participants Needed
28
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the effectiveness of initial triple combination therapy versus initial double oral therapy in adults with pulmonary arterial hypertension PAH who are either intermediate-high risk or intermediate-low risk with severe hemodynamic impairment. This phase IV, randomized, open-label trial aims to optimize treatment strategies for PAH by comparing the proportion of patients achieving low-risk status between the two treatments. The study focuses on patients with idiopathic, hereditary, drug-induced, connective tissue disease-associated, or corrected congenital heart disease-related PAH. Participants are randomly assigned to one of two groups one receives double oral therapy consisting of an endothelin receptor antagonist ERA and a phosphodiesterase type-5 inhibitor PDE-5i, while the other group receives initial triple therapy that includes the same double oral combination plus parenteral treprostinil administered subcutaneously or intravenously via an infusion pump. All medications start within three weeks of randomization, and patients in the treprostinil group receive training on pump use and medication management. Dose adjustments of treprostinil are made to reach a target or maximum tolerated dose over 24 weeks and beyond. Participants will be followed for 12 to 48 weeks with up to 10 visits, including phone calls and in-person assessments. The study evaluates risk status using a standardized four-strata risk-assessment tool, hemodynamic parameters via right heart catheterization, echocardiogram measures, and patient-reported outcomes such as quality of life and symptom questionnaires. Safety is monitored through routine care without additional invasive procedures beyond standard PAH management. The primary outcome is the achievement of low-risk status between weeks 12 and 48, with secondary outcomes assessing heart function, clinical worsening, survival, and quality of life changes.
CONDITIONS
Brief Title
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
Research Team
C
Clinical Project Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here